Eradivir Secures $10.25M for Influenza Study
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
- Latest
- Trending
Biotech firm Eradivir raises $10.25M for Phase 2a EV25 study, aiming to revolutionize influenza treatment.
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
Iovance Biotherapeutics has the potential to become a multiproduct company, and even if its stock doesn't soar quickly, it's still ...
Researchers have successfully developed a single-dose vaccine that prompts the production of T-cells and "memory" B cells to fight against ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.